Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in
near-vision restoration that has developed the Presbia Flexivue
Microlens™, a proprietary optical lens implant for treating presbyopia,
announced that Todd Cooper, President and CEO, is scheduled to present
at the Rodman & Renshaw 19th Annual Investment
Conference. The Conference will take place at the Lotte New York Palace
Hotel in New York City from September 10 to 12, 2017. Mr. Cooper will be
available for one-on-one meetings.
The presentation will provide an update on the status of the U.S.
clinical trial. "Presbia plans on submitting the fourth and final module
of the IDE study to the FDA in Q4, which is a major milestone towards
approval of the Presbia Flexivue Microlens™ in the U.S.," said Mr.
Details of the presentation are as follows:
Date: Monday, September 11, 2017
Time: 3:50 PM ET
Louis (4th Floor)
Information provided and
statements contained in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements only speak as of the date of this press release and Presbia
assumes no obligation to update the information included in this press
release. Statements made in this press release that are forward looking
in nature may involve risks and uncertainties. Accordingly, readers are
cautioned that any such forward-looking statements are not guarantees
and are subject to certain risks, uncertainties and assumptions that are
difficult to predict. Although Presbia believes that the expectations
reflected in such forward-looking statements are reasonable as of the
date made, expectations may prove to have been materially different from
the results expressed or implied by such forward-looking statements.
Unless otherwise required by law, Presbia also disclaims any obligation
to update its view of any such risks or uncertainties or to announce
publicly the result of any revisions to the forward-looking statements
made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic
device company that has developed and is currently marketing the
presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that
is implanted in a corneal pocket created by a femtosecond laser. The
Presbia Flexivue Microlens™ has received a CE mark for the European
Economic Area, allowing the lens to be marketed in over 30 countries
across Europe. A staged pivotal U.S. clinical trial for the Presbia
Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170907005527/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media